- Overview:
- This study evaluates the safety and effectiveness of a medication used for pediatric patients with Central Precocious Puberty.
- Staus:
- Enrolling
- Clinical Description:
- An Open-label, Single Arm, Multicenter, Phase III Study on the Efficacy, Safety, and Pharmacokinetics of FP-001 42 mg Controlled Release in Patients with Central (Gonadotropin-Dependent) Precocious Puberty.
- Target Age/Sex:
- Females, aged 2 – 8 years (inclusive), Males, aged 2 to 9 years (inclusive)
- Benefits:
- Participants will receive at no cost: 8 clinical visits, study product, study materials and increased physician oversight. Reimbursement for time and travel.
- Study Length:
- 8 Clinical Visits
- Link:
- ClinicalTrials.gov
